Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke.

Alim I, Caulfield JT, Chen Y, Swarup V, Geschwind DH, Ivanova E, Seravalli J, Ai Y, Sansing LH, Ste Marie EJ, Hondal RJ, Mukherjee S, Cave JW, Sagdullaev BT, Karuppagounder SS, Ratan RR.

Cell. 2019 May 16;177(5):1262-1279.e25. doi: 10.1016/j.cell.2019.03.032. Epub 2019 May 2.

PMID:
31056284
2.

Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors.

Zille M, Kumar A, Kundu N, Bourassa MW, Wong VSC, Willis D, Karuppagounder SS, Ratan RR.

eNeuro. 2019 Feb 15;6(1). pii: ENEURO.0263-18.2019. doi: 10.1523/ENEURO.0263-18.2019. eCollection 2019 Jan-Feb.

3.

Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons.

Xue Y, Zhan X, Sun S, Karuppagounder SS, Xia S, Dawson VL, Dawson TM, Laterra J, Zhang J, Ying M.

Stem Cells Transl Med. 2019 Feb;8(2):112-123. doi: 10.1002/sctm.18-0036. Epub 2018 Nov 1.

4.

Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease.

Kam TI, Mao X, Park H, Chou SC, Karuppagounder SS, Umanah GE, Yun SP, Brahmachari S, Panicker N, Chen R, Andrabi SA, Qi C, Poirier GG, Pletnikova O, Troncoso JC, Bekris LM, Leverenz JB, Pantelyat A, Ko HS, Rosenthal LS, Dawson TM, Dawson VL.

Science. 2018 Nov 2;362(6414). pii: eaat8407. doi: 10.1126/science.aat8407.

5.

N-acetylcysteine targets 5 lipoxygenase-derived, toxic lipids and can synergize with prostaglandin E2 to inhibit ferroptosis and improve outcomes following hemorrhagic stroke in mice.

Karuppagounder SS, Alin L, Chen Y, Brand D, Bourassa MW, Dietrich K, Wilkinson CM, Nadeau CA, Kumar A, Perry S, Pinto JT, Darley-Usmar V, Sanchez S, Milne GL, Pratico D, Holman TR, Carmichael ST, Coppola G, Colbourne F, Ratan RR.

Ann Neurol. 2018 Dec;84(6):854-872. doi: 10.1002/ana.25356. Epub 2018 Nov 29.

6.
7.

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.

Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, Kwon SH, Park YJ, Karuppagounder SS, Park H, Kim S, Oh N, Kim NA, Lee S, Brahmachari S, Mao X, Lee JH, Kumar M, An D, Kang SU, Lee Y, Lee KC, Na DH, Kim D, Lee SH, Roschke VV, Liddelow SA, Mari Z, Barres BA, Dawson VL, Lee S, Dawson TM, Ko HS.

Nat Med. 2018 Jul;24(7):931-938. doi: 10.1038/s41591-018-0051-5. Epub 2018 Jun 11.

8.

Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.

Xiong Y, Neifert S, Karuppagounder SS, Liu Q, Stankowski JN, Lee BD, Ko HS, Lee Y, Grima JC, Mao X, Jiang H, Kang SU, Swing DA, Iacovitti L, Tessarollo L, Dawson TM, Dawson VL.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1635-1640. doi: 10.1073/pnas.1712648115. Epub 2018 Jan 31.

9.

GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers.

Kim S, Yun SP, Lee S, Umanah GE, Bandaru VVR, Yin X, Rhee P, Karuppagounder SS, Kwon SH, Lee H, Mao X, Kim D, Pandey A, Lee G, Dawson VL, Dawson TM, Ko HS.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):798-803. doi: 10.1073/pnas.1700465115. Epub 2018 Jan 8.

10.

α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.

Yun SP, Kim D, Kim S, Kim S, Karuppagounder SS, Kwon SH, Lee S, Kam TI, Lee S, Ham S, Park JH, Dawson VL, Dawson TM, Lee Y, Ko HS.

Mol Neurodegener. 2018 Jan 8;13(1):1. doi: 10.1186/s13024-017-0233-5.

11.

c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

Brahmachari S, Karuppagounder SS, Ge P, Lee S, Dawson VL, Dawson TM, Ko HS.

J Parkinsons Dis. 2017;7(4):589-601. doi: 10.3233/JPD-171191.

12.

Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.

Xiong Y, Neifert S, Karuppagounder SS, Stankowski JN, Lee BD, Grima JC, Chen G, Ko HS, Lee Y, Swing D, Tessarollo L, Dawson TM, Dawson VL.

eNeuro. 2017 Mar 17;4(2). pii: ENEURO.0004-17.2017. doi: 10.1523/ENEURO.0004-17.2017. eCollection 2017 Mar-Apr.

13.

Neuronal Death After Hemorrhagic Stroke In Vitro and In Vivo Shares Features of Ferroptosis and Necroptosis.

Zille M, Karuppagounder SS, Chen Y, Gough PJ, Bertin J, Finger J, Milner TA, Jonas EA, Ratan RR.

Stroke. 2017 Apr;48(4):1033-1043. doi: 10.1161/STROKEAHA.116.015609. Epub 2017 Mar 1.

14.

Synaptic Plasticity onto Dopamine Neurons Shapes Fear Learning.

Pignatelli M, Umanah GKE, Ribeiro SP, Chen R, Karuppagounder SS, Yau HJ, Eacker S, Dawson VL, Dawson TM, Bonci A.

Neuron. 2017 Jan 18;93(2):425-440. doi: 10.1016/j.neuron.2016.12.030.

15.

Bioactive Flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers - Implications for Parkinson's Disease.

Smirnova NA, Kaidery NA, Hushpulian DM, Rakhman II, Poloznikov AA, Tishkov VI, Karuppagounder SS, Gaisina IN, Pekcec A, Leyen KV, Kazakov SV, Yang L, Thomas B, Ratan RR, Gazaryan IG.

Aging Dis. 2016 Dec 1;7(6):745-762. doi: 10.14336/AD.2016.0505. eCollection 2016 Dec.

16.

Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.

Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gonçalves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DA, Dawson VL, Ko HS, Dawson TM.

Science. 2016 Sep 30;353(6307). pii: aah3374.

17.

Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration.

Brahmachari S, Ge P, Lee SH, Kim D, Karuppagounder SS, Kumar M, Mao X, Shin JH, Lee Y, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Ko HS.

J Clin Invest. 2016 Aug 1;126(8):2970-88. doi: 10.1172/JCI85456. Epub 2016 Jun 27.

18.

Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate.

Sleiman SF, Henry J, Al-Haddad R, El Hayek L, Abou Haidar E, Stringer T, Ulja D, Karuppagounder SS, Holson EB, Ratan RR, Ninan I, Chao MV.

Elife. 2016 Jun 2;5. pii: e15092. doi: 10.7554/eLife.15092.

19.

Inhibition of HIF-prolyl-4-hydroxylases prevents mitochondrial impairment and cell death in a model of neuronal oxytosis.

Neitemeier S, Dolga AM, Honrath B, Karuppagounder SS, Alim I, Ratan RR, Culmsee C.

Cell Death Dis. 2016 May 5;7:e2214. doi: 10.1038/cddis.2016.107.

20.

Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models.

Karuppagounder SS, Alim I, Khim SJ, Bourassa MW, Sleiman SF, John R, Thinnes CC, Yeh TL, Demetriades M, Neitemeier S, Cruz D, Gazaryan I, Killilea DW, Morgenstern L, Xi G, Keep RF, Schallert T, Tappero RV, Zhong J, Cho S, Maxfield FR, Holman TR, Culmsee C, Fong GH, Su Y, Ming GL, Song H, Cave JW, Schofield CJ, Colbourne F, Coppola G, Ratan RR.

Sci Transl Med. 2016 Mar 2;8(328):328ra29. doi: 10.1126/scitranslmed.aac6008.

21.

Methamphetamine-induced dopaminergic toxicity prevented owing to the neuroprotective effects of salicylic acid.

Thrash-Williams B, Karuppagounder SS, Bhattacharya D, Ahuja M, Suppiramaniam V, Dhanasekaran M.

Life Sci. 2016 Jun 1;154:24-9. doi: 10.1016/j.lfs.2016.02.072. Epub 2016 Feb 27.

PMID:
26926078
22.

LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity.

Karuppagounder SS, Xiong Y, Lee Y, Lawless MC, Kim D, Nordquist E, Martin I, Ge P, Brahmachari S, Jhaldiyal A, Kumar M, Andrabi SA, Dawson TM, Dawson VL.

J Chem Neuroanat. 2016 Oct;76(Pt B):90-97. doi: 10.1016/j.jchemneu.2016.01.007. Epub 2016 Jan 22.

23.

Corrigendum: Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss.

Lee Y, Karuppagounder SS, Shin JH, Lee YI, Ko HS, Swing D, Jiang H, Kang SU, Lee BD, Kang HC, Kim D, Tessarollo L, Dawson VL, Dawson TM.

Nat Neurosci. 2015 Dec;18(12):1861. doi: 10.1038/nn1215-1861a. No abstract available.

PMID:
26605883
24.

Metabolism and epigenetics in the nervous system: Creating cellular fitness and resistance to neuronal death in neurological conditions via modulation of oxygen-, iron-, and 2-oxoglutarate-dependent dioxygenases.

Karuppagounder SS, Kumar A, Shao DS, Zille M, Bourassa MW, Caulfield JT, Alim I, Ratan RR.

Brain Res. 2015 Dec 2;1628(Pt B):273-287. doi: 10.1016/j.brainres.2015.07.030. Epub 2015 Jul 29. Review.

25.

Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition.

Sleiman SF, Olson DE, Bourassa MW, Karuppagounder SS, Zhang YL, Gale J, Wagner FF, Basso M, Coppola G, Pinto JT, Holson EB, Ratan RR.

J Neurosci. 2014 Oct 22;34(43):14328-37. doi: 10.1523/JNEUROSCI.1010-14.2014. Erratum in: J Neurosci. 2015 Jan 7;35(1):438.

26.

Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.

Lu W, Karuppagounder SS, Springer DA, Allen MD, Zheng L, Chao B, Zhang Y, Dawson VL, Dawson TM, Lenardo M.

Nat Commun. 2014 Sep 15;5:4930. doi: 10.1038/ncomms5930.

27.

Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis.

Andrabi SA, Umanah GK, Chang C, Stevens DA, Karuppagounder SS, Gagné JP, Poirier GG, Dawson VL, Dawson TM.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10209-14. doi: 10.1073/pnas.1405158111. Epub 2014 Jul 1.

28.

Proneural transcription factor Atoh1 drives highly efficient differentiation of human pluripotent stem cells into dopaminergic neurons.

Sagal J, Zhan X, Xu J, Tilghman J, Karuppagounder SS, Chen L, Dawson VL, Dawson TM, Laterra J, Ying M.

Stem Cells Transl Med. 2014 Aug;3(8):888-98. doi: 10.5966/sctm.2013-0213. Epub 2014 Jun 5.

29.

The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.

Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS.

Sci Rep. 2014 May 2;4:4874. doi: 10.1038/srep04874.

30.

Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin.

Aleyasin H, Karuppagounder SS, Kumar A, Sleiman S, Basso M, Ma T, Siddiq A, Chinta SJ, Brochier C, Langley B, Haskew-Layton R, Bane SL, Riggins GJ, Gazaryan I, Starkov AA, Andersen JK, Ratan RR.

Antioxid Redox Signal. 2015 Jan 10;22(2):121-34. doi: 10.1089/ars.2013.5595.

31.

MicroRNA-132 dysregulation in Toxoplasma gondii infection has implications for dopamine signaling pathway.

Xiao J, Li Y, Prandovszky E, Karuppagounder SS, Talbot CC Jr, Dawson VL, Dawson TM, Yolken RH.

Neuroscience. 2014 May 30;268:128-38. doi: 10.1016/j.neuroscience.2014.03.015. Epub 2014 Mar 18.

32.

Elucidating the neurotoxic effects of MDMA and its analogs.

Karuppagounder SS, Bhattacharya D, Ahuja M, Suppiramaniam V, Deruiter J, Clark R, Dhanasekaran M.

Life Sci. 2014 Apr 17;101(1-2):37-42. doi: 10.1016/j.lfs.2014.02.010. Epub 2014 Feb 19.

PMID:
24560859
33.

Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss.

Lee Y, Karuppagounder SS, Shin JH, Lee YI, Ko HS, Swing D, Jiang H, Kang SU, Lee BD, Kang HC, Kim D, Tessarollo L, Dawson VL, Dawson TM.

Nat Neurosci. 2013 Oct;16(10):1392-400. doi: 10.1038/nn.3500. Epub 2013 Aug 25. Erratum in: Nat Neurosci. 2015 Dec;18(12):1861.

34.

Assessment of therapeutic potential of amantadine in methamphetamine induced neurotoxicity.

Thrash-Williams B, Ahuja M, Karuppagounder SS, Uthayathas S, Suppiramaniam V, Dhanasekaran M.

Neurochem Res. 2013 Oct;38(10):2084-94. doi: 10.1007/s11064-013-1117-x. Epub 2013 Aug 6.

PMID:
23918203
35.

Selective inhibition of phosphodiesterase 5 enhances glutamatergic synaptic plasticity and memory in mice.

Uthayathas S, Parameshwaran K, Karuppagounder SS, Ahuja M, Dhanasekaran M, Suppiramaniam V.

Synapse. 2013 Nov;67(11):741-7. doi: 10.1002/syn.21676. Epub 2013 Jun 3.

PMID:
23620198
36.

In vitro ischemia suppresses hypoxic induction of hypoxia-inducible factor-1α by inhibition of synthesis and not enhanced degradation.

Karuppagounder SS, Basso M, Sleiman SF, Ma TC, Speer RE, Smirnova NA, Gazaryan IG, Ratan RR.

J Neurosci Res. 2013 Aug;91(8):1066-75. doi: 10.1002/jnr.23204. Epub 2013 Mar 4.

37.

Sodium salicylate protects against rotenone-induced parkinsonism in rats.

Madathil SK, Karuppagounder SS, Mohanakumar KP.

Synapse. 2013 Aug;67(8):502-14. doi: 10.1002/syn.21658. Epub 2013 Mar 27.

PMID:
23447126
38.

Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke.

Speer RE, Karuppagounder SS, Basso M, Sleiman SF, Kumar A, Brand D, Smirnova N, Gazaryan I, Khim SJ, Ratan RR.

Free Radic Biol Med. 2013 Sep;62:26-36. doi: 10.1016/j.freeradbiomed.2013.01.026. Epub 2013 Jan 31. Review.

39.

Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats.

Karuppagounder SS, Madathil SK, Pandey M, Haobam R, Rajamma U, Mohanakumar KP.

Neuroscience. 2013 Apr 16;236:136-48. doi: 10.1016/j.neuroscience.2013.01.032. Epub 2013 Jan 26.

PMID:
23357119
40.

Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats.

Madathil KS, Karuppagounder SS, Haobam R, Varghese M, Rajamma U, Mohanakumar KP.

Neurochem Int. 2013 Apr;62(5):674-83. doi: 10.1016/j.neuint.2013.01.007. Epub 2013 Jan 23.

PMID:
23353925
41.

Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration.

Sleiman SF, Berlin J, Basso M, Karuppagounder SS, Rohr J, Ratan RR.

Pharmaceuticals (Basel). 2011 Aug 22;4(8):1183-1195.

42.

Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?

Karuppagounder SS, Ratan RR.

J Cereb Blood Flow Metab. 2012 Jul;32(7):1347-61. doi: 10.1038/jcbfm.2012.28. Epub 2012 Mar 14. Review.

43.

Investigate the chronic neurotoxic effects of diquat.

Karuppagounder SS, Ahuja M, Buabeid M, Parameshwaran K, Abdel-Rehman E, Suppiramaniam V, Dhanasekaran M.

Neurochem Res. 2012 May;37(5):1102-11. doi: 10.1007/s11064-012-0715-3. Epub 2012 Feb 14.

PMID:
22331545
44.

Developmental nicotine exposure induced alterations in behavior and glutamate receptor function in hippocampus.

Parameshwaran K, Buabeid MA, Karuppagounder SS, Uthayathas S, Thiruchelvam K, Shonesy B, Dityatev A, Escobar MC, Dhanasekaran M, Suppiramaniam V.

Cell Mol Life Sci. 2012 Mar;69(5):829-41. doi: 10.1007/s00018-011-0805-4. Epub 2011 Oct 28.

PMID:
22033836
45.

Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents.

Shonesy BC, Thiruchelvam K, Parameshwaran K, Rahman EA, Karuppagounder SS, Huggins KW, Pinkert CA, Amin R, Dhanasekaran M, Suppiramaniam V.

Neurobiol Aging. 2012 Feb;33(2):430.e5-18. doi: 10.1016/j.neurobiolaging.2010.12.002. Epub 2011 Jan 21.

PMID:
21256630
46.

Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function.

Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM.

Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16691-6. doi: 10.1073/pnas.1006083107. Epub 2010 Sep 7.

47.

Neurotoxic effects of methamphetamine.

Thrash B, Karuppagounder SS, Uthayathas S, Suppiramaniam V, Dhanasekaran M.

Neurochem Res. 2010 Jan;35(1):171-9. doi: 10.1007/s11064-009-0042-5. Epub 2009 Aug 21.

PMID:
19697126
48.

Oxidant-induced changes in mitochondria and calcium dynamics in the pathophysiology of Alzheimer's disease.

Gibson GE, Karuppagounder SS, Shi Q.

Ann N Y Acad Sci. 2008 Dec;1147:221-32. doi: 10.1196/annals.1427.038. Review.

49.

Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease.

Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE.

Neurochem Int. 2009 Feb;54(2):111-8. doi: 10.1016/j.neuint.2008.10.008. Epub 2008 Nov 8.

50.

Paraquat and maneb induced neurotoxicity.

Thrash B, Uthayathas S, Karuppagounder SS, Suppiramaniam V, Dhanasekaran M.

Proc West Pharmacol Soc. 2007;50:31-42. Review.

PMID:
18605226

Supplemental Content

Loading ...
Support Center